Cyclerion Therapeutics (NASDAQ:CYCN) Trading 9.6% Higher

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s share price was up 9.6% during trading on Tuesday . The stock traded as high as $2.94 and last traded at $2.85. Approximately 3,287 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 4,324 shares. The stock had previously closed at $2.60.

Cyclerion Therapeutics Stock Performance

The firm has a fifty day simple moving average of $2.86 and a two-hundred day simple moving average of $2.94.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cyclerion Therapeutics stock. Tyndall Capital Partners L P boosted its stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 164,429 shares of the company’s stock after purchasing an additional 16,717 shares during the quarter. Cyclerion Therapeutics makes up 100.0% of Tyndall Capital Partners L P’s investment portfolio, making the stock its largest position. Tyndall Capital Partners L P owned about 6.71% of Cyclerion Therapeutics worth $551,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.